Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alvocidib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 known ✓ | P24941 | 14/20 | 1.00 |
| ▸ | CDK4 known ✓ | P11802 | 12/20 | 1.00 |
| ▸ | CDK1 known ✓ | P06493 | 11/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 10/20 | 1.00 |
| ▸ | CDK7 known ✓ | P50613 | 3/20 | 1.00 |
| ▸ | CDK6 known ✓ | Q00534 | 2/20 | 1.00 |
| ▸ | CCND1 | P24385 | 11/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 9/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 9/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 8/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 6/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 6/20 | 1.00 |
| ▸ | GSK3A | P49840 | 4/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 4/20 | 1.00 |
| ▸ | GSK3B | P49841 | 3/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alvocidib SCHEMBL5868074 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL29351027 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL29577824 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL12445809 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL29388553 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL3652 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL3651 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL16927354 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Flavopyridol SCHEMBL22580715 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 | |
| Alvocidib SCHEMBL28199338 | 1.00 | CDK2 (1.00) | CDK2CDK4CDK1CCND1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196943-A1 | DR5 AGONIST AND PLK1 INHIBITOR OR CDK INHIBITOR COMBINATION THERAPY | Inhibrx, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20220220072-A1 | METHOD FOR PRODUCING CIS-(-) FLOCINOPIPERIDOL | Sumitomo Pharma Co., Ltd. (JP) | 2022-07-14 | — | — | US | disclosed |
| EP-3527574-B1 | ALVOCIDIB PRODRUGS HAVING INCREASED BIOAVAILABILITY | SUMITOMO DAINIPPON PHARMA ONCOLOGY INC (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2021236721-A1 | METHODS FOR PREVENTING, REVERSING OR TREATING A COVID-19 INFECTION | BROWN UNIVERSITY (US) | 2021-11-25 | — | — | WO | disclosed |
| EP-3129371-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20190134033-A1 | PHARMACEUTICAL COMBINATIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-05-09 | — | — | US | disclosed |
| EP-2831282-B1 | PREDICTIVE BIOMARKER USEFUL FOR CANCER THERAPY MEDIATED BY A CDK INHIBITOR | MERCK SHARP & DOHME (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-2225235-B1 | THIAZOLE CARBOXAMIDE DERIVATIVES AND THEIR USE TO TREAT CANCER | MERCK SHARP & DOHME (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-2752422-B1 | Stereoselective synthesis of phosphorus containing actives | GILEAD PHARMASSET LLC (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2078003-B1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20070032495-A1 | Pyrazolotriazines as kinase inhibitors | MERCK SHARP & DOHME LLC | 2007-02-08 | — | — | US | disclosed |
| US-20070032495-A1 | Pyrazolotriazines as kinase inhibitors | MERCK SHARP & DOHME LLC | 2007-02-08 | — | — | US | disclosed |
| US-7166602-B2 | Pyrazolotriazines as kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166602-B2 | Pyrazolotriazines as kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| US-20040063715-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-20040063715-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220072-A1 | METHOD FOR PRODUCING CIS-(-) FLOCINOPIPERIDOL | DHFR, DHPS, TKT | CDK2 1217/4885CDK4 209/4885CDK1 2289/4885 |
| US-20040063715-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | CDK2 1/4885CDK4 5/4885CDK1 3/4885 |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | CDK2 1/4885CDK4 4/4885CDK1 3/4885 |
| US-20070032495-A1 | Pyrazolotriazines as kinase inhibitors | CDK2, CDK5, CDK1 | CDK2 1/4885CDK4 11/4885CDK1 3/4885 |
| US-20190134033-A1 | PHARMACEUTICAL COMBINATIONS | TP53, HRAS, KRAS | CDK2 266/4885CDK4 194/4885CDK1 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.